Skip to main content
Premium Trial:

Request an Annual Quote

Pronota Raises Additional $1.8M in Financing

a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) —Biomarker developer Pronota has raised an additional €1.5million ($1.8 million) for a total of €7.9 million in its Series B financing round, the company said yesterday.

The Ghent, Belgium-based firm plans to use the funds raised in the round to develop technologies for cardio-renal, pre-eclampsia, sepsis, and ovarian cancer diagnostics.

The latest financing came from MedSciences Capital, the venture arm of the Dutch bank Kempen & Co., and earlier investors in the Series B round included Gimy, Biotech Fund Flanders, LSP, JJDC, KBC Private Equity, VIB, MP Healthcare Venture Management, and Baekeland Fund.

Pronota said that its central platform, which mines for low-abundance protein biomarkers in blood, has been validated by its cardio-renal and other programs, and that it now plans to launch its first diagnostic product in 2012.

The Scan

Transplant Tests Edited Pig Kidneys

The Associated Press reports a University of Alabama-Birmingham team transplanted genetically modified pig kidneys into a brain-dead human patient.

UK Changes Some Gene-Edited Crop Rules

A new law may enable gene-edited crops to be sold in the UK within about five years, New Scientist says.

Pill Works Against Omicron in Lab

Pfizer's antiviral pill to treat SARS-CoV-2 appears to work against the Omicron variant, the Wall Street Journal reports.

Nature Papers Find Genetic Risk Factor for Smell, Taste Loss in COVID-19; Analyze TB Granulomas

In Nature this week: genome-wide association study find locus linked to the risk COVID-19 patients losing their sense of taste or smell, and more.